Genmab — December 2012
-
5.01 part b
-
kombi studie revlimid
-
hexabody
-
expense will blive 100% funded af janssen
-
og derfor vil burn reducerer
-
profitabilitet afhænger af milestones. Så det handler videre om sustainaibility. Det vil sige to type profitability
-
med og uden milestones
-
yes yes
-
præcis
-
endelig en mand der siger det som det er
-
Prettige Feestdagen. We know have wines
-
den kommer vi meget tilbage til
-
slut
-
Det var godt nok spændende det her
-
det var vildt
-
jeg tror aldrrig vi har fået så mange info før
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind